Saltar al contenido
MilliporeSigma

Z101

Sigma-Aldrich

Zimelidine dihydrochloride

solid

Sinónimos:

(Z)-3-(4-Bromophenyl)-N,N-dimethyl-3-(3-pyridinyl)-2-propen-1-amine dihydrochloride

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C16H17BrN2 · 2HCl
Número de CAS:
Peso molecular:
390.15
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

form

solid

color

white

solubility

0.1 M HCl: 45 mg/mL
H2O: 66 mg/mL

originator

AstraZeneca

SMILES string

Cl[H].Cl[H].[H]\C(CN(C)C)=C(/c1ccc(Br)cc1)c2cccnc2

InChI

1S/C16H17BrN2.2ClH/c1-19(2)11-9-16(14-4-3-10-18-12-14)13-5-7-15(17)8-6-13;;/h3-10,12H,11H2,1-2H3;2*1H/b16-9-;;

InChI key

CXGURXWCQYHDIR-ULPVBNQHSA-N

Application

Zimelidine dihydrochloride has been used as a serotonin transport inhibitor to study its inhibitory role in the uptake of exogenous serotonin by bipolar cells.

Biochem/physiol Actions

Zimelidine, an antidepressant, is a specific 5-hydroxytryptamine (5-HT) reuptake inhibitor, that can be used in treating phobic anxiety. It is very effective and can be tolerated well in elderly individuals. This serotonin transport inhibitor is less likely than other antidepressants to have cardiovascular side effects. Unlike other tricyclic antidepressants, Zimelidine might promote weight loss but not weight gain.

Features and Benefits

This compound is featured on the Biogenic Amine Transporters page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold with the permission of Astra AB.

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

R W Fuller
Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques, 45, 167-204 (1995-01-01)
Fluoxetine, zimelidine, sertraline, paroxetine, fluvoxamine, indalpine and citalopram are the selective inhibitors of serotonin uptake that have been most widely studied. Some of these compounds are or have been used clinically in the treatment of mental depression, obsessive-compulsive disorder and
T Egashira et al.
Japanese journal of pharmacology, 81(1), 115-121 (1999-12-02)
The effects of the antidepressant drugs zimeldine, imipramine, maprotiline or nomifensine on mitochondrial monoamine oxidase (MAO) activity in mouse, rat, dog and monkey brains were compared in vitro. Mouse, rat, dog and monkey brain MAO-B activities were inhibited by zimeldine
M G Frank et al.
Brain research, 768(1-2), 287-293 (1997-11-22)
Chronic postnatal exposure to clomipramine (CMI), a monoamine uptake inhibitor, results in persistent alterations in adult rat REM sleep. These effects have been ascribed to CMI's ability to block neonatal active sleep (AS). However, these effects have not been obtained
S Esteban et al.
Naunyn-Schmiedeberg's archives of pharmacology, 360(2), 135-143 (1999-09-24)
The effects of antidepressant drugs on the synthesis of noradrenaline and serotonin (5-HT) were assessed using the accumulation of 3,4-dihydroxyphenylalanine (dopa) and 5-hydroxytryptophan (5-HTP) after decarboxylase inhibition as a measure of the rate of tyrosine and tryptophan hydroxylation in the
Yoshiko Okai et al.
Journal of pharmacological and toxicological methods, 105, 106893-106893 (2020-07-04)
Drug-induced inotropic change is a risk factor in drug development; thus, de-risking is desired in the early stages of drug development. Unlike proarrhythmic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), few in vitro models were validated to

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico